John P. Hamill, Senior VP/CFO/Prin Fin & Acct Ofcr at Aprea Therapeutics, Inc. (APRE), bought 50 shares at $2.46 ($123) on 2024-10-11, disclosed to the SEC on 2024-10-16.
Open-market purchase of $123 APRE by Senior VP/CFO/Prin Fin & Acct Ofcr. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| APRE | BUY | 2024-10-15 | $1K | — | Filing → |
| APRE | BUY | 2024-03-14 | $7K | — | Filing → |
| WINT | BUY | 2022-07-26 | $1K | — | Filing → |